270 related articles for article (PubMed ID: 38439728)
1. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
Róbert L; Kovács A; Sárdy M; Fábián M
Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
Sinagra JL; Vedovelli C; Binazzi R; Salemme A; Moro F; Mazzanti C; Didona B; Di Zenzo G
Front Immunol; 2021; 12():665522. PubMed ID: 33936104
[TBL] [Abstract][Full Text] [Related]
3. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
[TBL] [Abstract][Full Text] [Related]
4. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.
Koszegi B; Stone C; Murrell DF
Front Med (Lausanne); 2023; 10():1149742. PubMed ID: 36999066
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy improves recalcitrant Pemphigus vulgaris.
Noormohammadpour P; Ehsani A; Mortazavi H; Daneshpazhooh M; Balighi K; Mofidi M; Gholamali F; Sadeghinia A
EXCLI J; 2015; 14():109-16. PubMed ID: 26417354
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
12. Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.
Jafri ZA; Walia S; Ivanic MG; Wu JJ
J Dermatolog Treat; 2022 May; 33(3):1606-1607. PubMed ID: 33375865
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.
Kasperkiewicz M; Shimanovich I; Meier M; Schumacher N; Westermann L; Kramer J; Zillikens D; Schmidt E
Br J Dermatol; 2012 Jan; 166(1):154-60. PubMed ID: 21910700
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in pemphigus.
Hebert V; Joly P
Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
Antonucci A; Negosanti M; Tabanelli M; Varotti C
J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
[TBL] [Abstract][Full Text] [Related]
17. Pemphigus.
Schmidt E; Kasperkiewicz M; Joly P
Lancet; 2019 Sep; 394(10201):882-894. PubMed ID: 31498102
[TBL] [Abstract][Full Text] [Related]
18. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
19. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
[TBL] [Abstract][Full Text] [Related]
20. Pemphigus vulgaris: a case report.
Thanmai JV; Ramlal G; Tejaswi K; Mounica IL
Pan Afr Med J; 2022; 42():184. PubMed ID: 36212921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
